Developer docs
API playgroundTry for free, no card

Search company profiles

Protium Science

Full company profile

uuid00039mx

Namestring
Protium Science
Legal namestring
Protium Science
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Protium Science is a Seongnam, South Korea-based contract development, analysis, and manufacturing organization (CDAMO) founded in 2021 that provides end-to-end biopharmaceutical services spanning cell line development, upstream and downstream process development, GMP manufacturing, and analytical method qualification. The company positions itself as a one-stop biosimilar-focused service provider, having completed more than 630 projects for over 130 domestic bio companies, with a workforce of 51–100 employees carrying global biosimilar experience.

Revenue is generated through multi-year fee-for-service contracts and turnkey CDO agreements, with disclosed annual revenue scaling from approximately 1.6 billion KRW in 2022 to 6.7 billion KRW in 2024, and annual order intake of approximately 21.6 billion KRW recorded in 2025 against a cumulative order book of roughly 40 billion KRW as of October 2025. The customer base is concentrated in Korean biosimilar developers, with Kyongdong Pharmaceutical disclosed as a named strategic counterparty under a recent biosimilar contract, and seven customers having signed turnkey CDO contracts totaling 20 billion KRW.

The business model combines capital-efficient fee-for-service work with longer-duration turnkey programs, supplemented by a strategic AI partnership with Cellkey AI (June 2025) to embed predictive analytics into process development. Backed by approximately $15.9M in equity from investors including TiumBio and HK inno.N, the company announced plans for a general stock (KOSDAQ) listing in October 2025 alongside its first overseas business development activity at BPI2025 in Boston.

Short descriptiontext

Protium Science is a South Korean CDAMO (contract development, analysis, and manufacturing organization) founded in 2021 that provides end-to-end biosimilar services — cell line development, process development, GMP manufacturing, and analytical qualification — to Korean biopharma sponsors, with 130+ customers and 630+ projects completed.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical contract development, contract manufacturing services, cell line development, antibody-drug conjugate services, analytical testing services
Industry4 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAF
Analytical Development & QC Testing (Release/Stability/Potency)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Contract Development and Manufacturing (CDMO/CDAMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CDAMO Services (CDO, CAO, CMO)
TypeProfessional Services
Description

Revenue generated from contracted development (CDO), contracted analysis (CAO), and contracted manufacturing (CMO) services. The company provides comprehensive bio-pharmaceutical development services from early-stage research through commercial production, with recent growth driven by CDO turnkey contracts. Services are priced on a project basis with revenue recognized as services are delivered.

protiumscience.com
2ADC Development Services
TypeProfessional Services
Description

Specialized antibody-drug conjugate development services including conjugation, purification, and analysis.

protiumscience.com
3Investment-Linked Program
TypeManaged Services
Description

Investment-linked program combining CDMO synergies to support customer growth and successful subsequent development.

protiumscience.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Protium Science is a CDAMO (Contract Development, Analysis, Manufacturing Organization) providing integrated biopharmaceutical development services from cell line development through GMP production. The company offers three core service pillars—CDO (contract development), CAO (contract analysis), and CMO (contract manufacturing)—with specialized capabilities in advanced modalities including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADC), peptides, and viral vectors. Services are delivered on a project-contract basis to pharmaceutical and biotech customers primarily in South Korea.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 630+ cumulative projects completed over 3 years
+2 more records
Product overview1 text field

Protium Science operates as a CDAMO (Contract Development, Analysis, Manufacturing Organization) — a one-stop provider of biopharmaceutical contract services. Its core portfolio spans three integrated service pillars: CDO (contract development), CAO (contract analysis), and CMO (contract manufacturing), with specialized offerings in ADC (antibody-drug conjugate) development and lyophilization formulation services. The company additionally offers AI-integrated process optimization through a partnership with Cellkey AI, and collaborative GMP manufacturing via a partnership with STgen Bio. The CDAMO model provides clients with end-to-end support from cell line and process development through clinical and commercial production, linked to investment-linked program support to accelerate client growth.

Product and service1 record
1CDO (Contract Development Organization / 위탁개발)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-30
Description

Biosimilar contracted development agreement signed on September 30, 2025, supporting Kyongdong Pharmaceutical's expansion from synthetic drugs into bio-pharmaceuticals. The partnership leverages Protium Science's CDAMO expertise to advance Kyongdong's core biosimilar projects. This contract builds on a 2024 MOU for antibody drug development and demonstrates validated technical capabilities through successful project execution.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-11
Description

Strategic MOU signed on June 11, 2025 combining Protium Science's advanced CDAMO capabilities with Cellkey AI's data-driven AI analysis and prediction technology. The partnership aims to integrate AI across the entire bio-pharmaceutical development and production process for maximized efficiency. Specific collaboration areas include AI-based cell line development optimization, real-time culture and purification process data analysis, production yield prediction and anomaly detection, and AI-based quality control automation system development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

One of the world's largest CDMOs with full-spectrum biologics and cell/gene therapy services. Comparable to Protium as a benchmark competitor for CDAMO-type engagements in biologics, ADC, and cell/gene therapy, though Lonza operates at global scale.

TypeDirect peer
Description

Korean biotech developing bispecific antibodies and ADCs with process development capabilities. Comparable to Protium because it works across overlapping modalities (Bsp-Ab, ADC) and represents both a potential CDAMO customer and a specialist competitor for advanced-modality work.

TypeBroad incumbent
Description

Korea's largest biologics CDMO offering end-to-end development, manufacturing, and analytical services. Comparable because it competes for the same Korean biopharma clients across mAb, ADC, and biosimilar modalities, but at vastly greater scale and capacity.

TypeBroad incumbent
Description

Korean CDMO with biologics manufacturing facilities and development services. Comparable to Protium because it serves Korean pharma/biotech with biologics CDMO capabilities, including biosimilars, but is significantly larger and more established.

TypeDirect peer
Description

Korean biosimilar and biologics developer with substantial in-house manufacturing capacity. Comparable to Protium because it sits at the intersection of biosimilar development and CDMO-style capacity and is a potential competitor or partner for Korean biosimilar CDO work.

TypeDirect peer
Description

Korean biopharma CDMO used by Protium as its third-party GMP manufacturing partner. Directly comparable because it offers GMP biologics manufacturing to Korean clients and is referenced in Protium's own service offering as the bridge to commercial-scale GMP supply.

TypeBroad incumbent
Description

Korean biopharmaceutical company with vaccine and bio CDMO capabilities. Comparable to Protium as a Korean-headquartered life-sciences services platform with development and manufacturing operations, though SK Bioscience is far larger and more diversified.

TypeBroad incumbent
Description

Global biologics CDMO offering end-to-end development and manufacturing services for mAb, ADC, and recombinant proteins. Comparable to Protium because it competes for the same biologics outsourcing budgets across modalities, including in the Korean biosimilar market.

9Binex
TypeDirect peer
Description

Mid-sized Korean biopharmaceutical CDMO with development and manufacturing services across vaccines and biologics. Comparable to Protium as a Korean-headquartered, sub-scale biologics CDMO serving domestic pharma and biotech clients.

TypeBroad incumbent
Description

Korean biopharmaceutical company with plasma-derived products, vaccines, and CDMO activities. Comparable because it both produces biologics and offers CDMO-related services to Korean partners, making it a potential competitor and customer.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Protium Science

Biopharmaceutical Contract Development and Manufacturing (CDMO/CDAMO)protiumscience.com

Protium Science is a South Korean CDAMO (contract development, analysis, and manufacturing organization) founded in 2021 that provides end-to-end biosimilar services — cell line development, process development, GMP manufacturing, and analytical qualification — to Korean biopharma sponsors, with 130+ customers and 630+ projects completed.

What Protium Science does

Protium Science is a Seongnam, South Korea-based contract development, analysis, and manufacturing organization (CDAMO) founded in 2021 that provides end-to-end biopharmaceutical services spanning cell line development, upstream and downstream process development, GMP manufacturing, and analytical method qualification. The company positions itself as a one-stop biosimilar-focused service provider, having completed more than 630 projects for over 130 domestic bio companies, with a workforce of 51–100 employees carrying global biosimilar experience.

Revenue is generated through multi-year fee-for-service contracts and turnkey CDO agreements, with disclosed annual revenue scaling from approximately 1.6 billion KRW in 2022 to 6.7 billion KRW in 2024, and annual order intake of approximately 21.6 billion KRW recorded in 2025 against a cumulative order book of roughly 40 billion KRW as of October 2025. The customer base is concentrated in Korean biosimilar developers, with Kyongdong Pharmaceutical disclosed as a named strategic counterparty under a recent biosimilar contract, and seven customers having signed turnkey CDO contracts totaling 20 billion KRW.

The business model combines capital-efficient fee-for-service work with longer-duration turnkey programs, supplemented by a strategic AI partnership with Cellkey AI (June 2025) to embed predictive analytics into process development. Backed by approximately $15.9M in equity from investors including TiumBio and HK inno.N, the company announced plans for a general stock (KOSDAQ) listing in October 2025 alongside its first overseas business development activity at BPI2025 in Boston.

Protium Science firmographics

Firmographics
Name
Protium Science
Legal name
Protium Science
Website
https://protiumscience.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Protium Science is a South Korean CDAMO (contract development, analysis, and manufacturing organization) founded in 2021 that provides end-to-end biosimilar services — cell line development, process development, GMP manufacturing, and analytical qualification — to Korean biopharma sponsors, with 130+ customers and 630+ projects completed.
Ownership category
akta.pro rank

Protium Science industry classification

Industry
Product category
Biopharmaceutical Contract Development and Manufacturing (CDMO/CDAMO)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAF
Analytical Development & QC Testing (Release/Stability/Potency)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Biopharmaceutical contract development
  • Contract manufacturing services
  • Cell line development
  • Antibody-drug conjugate services
  • Analytical testing services

Where Protium Science is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Protium Science business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. CDAMO Services (CDO, CAO, CMO): Revenue generated from contracted development (CDO), contracted analysis (CAO), and contracted manufacturing (CMO) services. The company provides comprehensive bio-pharmaceutical development services from early-stage research through commercial production, with recent growth driven by CDO turnkey contracts. Services are priced on a project basis with revenue recognized as services are delivered.
  2. ADC Development Services: Specialized antibody-drug conjugate development services including conjugation, purification, and analysis.
  3. Investment-Linked Program: Investment-linked program combining CDMO synergies to support customer growth and successful subsequent development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Protium Science product offering

Product offering

Core offering

Protium Science is a CDAMO (Contract Development, Analysis, Manufacturing Organization) providing integrated biopharmaceutical development services from cell line development through GMP production. The company offers three core service pillars—CDO (contract development), CAO (contract analysis), and CMO (contract manufacturing)—with specialized capabilities in advanced modalities including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADC), peptides, and viral vectors. Services are delivered on a project-contract basis to pharmaceutical and biotech customers primarily in South Korea.

Product overview

Protium Science operates as a CDAMO (Contract Development, Analysis, Manufacturing Organization) — a one-stop provider of biopharmaceutical contract services. Its core portfolio spans three integrated service pillars: CDO (contract development), CAO (contract analysis), and CMO (contract manufacturing), with specialized offerings in ADC (antibody-drug conjugate) development and lyophilization formulation services. The company additionally offers AI-integrated process optimization through a partnership with Cellkey AI, and collaborative GMP manufacturing via a partnership with STgen Bio. The CDAMO model provides clients with end-to-end support from cell line and process development through clinical and commercial production, linked to investment-linked program support to accelerate client growth.

Differentiator

Problem solved

Functional benefit

Products and services

  • CDO (Contract Development Organization / 위탁개발)

Quantifiable outcome

  • 630+ cumulative projects completed over 3 years
  • +2 more outcomes

Companies that use Protium Science

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Protium Science technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Protium Science partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Kyongdong Pharmaceutical (경동제약)flagshipStrategic or Co-development Partner · 30 September 2025Biosimilar contracted development agreement signed on September 30, 2025, supporting Kyongdong Pharmaceutical's expansion from synthetic drugs into bio-pharmaceuticals. The partnership leverages Protium Science's CDAMO expertise to advance Kyongdong's core biosimilar projects. This contract builds on a 2024 MOU for antibody drug development and demonstrates validated technical capabilities through successful project execution.
  • Cellkey AI (셀키에이아이)coreTechnology or Integration · 11 June 2025Strategic MOU signed on June 11, 2025 combining Protium Science's advanced CDAMO capabilities with Cellkey AI's data-driven AI analysis and prediction technology. The partnership aims to integrate AI across the entire bio-pharmaceutical development and production process for maximized efficiency. Specific collaboration areas include AI-based cell line development optimization, real-time culture and purification process data analysis, production yield prediction and anomaly detection, and AI-based quality control automation system development.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Protium Science competitors and assessment

Company assessment

Others

  • Lonza Group: One of the world's largest CDMOs with full-spectrum biologics and cell/gene therapy services. Comparable to Protium as a benchmark competitor for CDAMO-type engagements in biologics, ADC, and cell/gene therapy, though Lonza operates at global scale.

Direct peers

  • ABL Bio: Korean biotech developing bispecific antibodies and ADCs with process development capabilities. Comparable to Protium because it works across overlapping modalities (Bsp-Ab, ADC) and represents both a potential CDAMO customer and a specialist competitor for advanced-modality work.
  • Celltrion: Korean biosimilar and biologics developer with substantial in-house manufacturing capacity. Comparable to Protium because it sits at the intersection of biosimilar development and CDMO-style capacity and is a potential competitor or partner for Korean biosimilar CDO work.
  • STgen Bio: Korean biopharma CDMO used by Protium as its third-party GMP manufacturing partner. Directly comparable because it offers GMP biologics manufacturing to Korean clients and is referenced in Protium's own service offering as the bridge to commercial-scale GMP supply.
  • Binex: Mid-sized Korean biopharmaceutical CDMO with development and manufacturing services across vaccines and biologics. Comparable to Protium as a Korean-headquartered, sub-scale biologics CDMO serving domestic pharma and biotech clients.

Broad incumbents

  • Samsung Biologics: Korea's largest biologics CDMO offering end-to-end development, manufacturing, and analytical services. Comparable because it competes for the same Korean biopharma clients across mAb, ADC, and biosimilar modalities, but at vastly greater scale and capacity.
  • Lotte Biologics: Korean CDMO with biologics manufacturing facilities and development services. Comparable to Protium because it serves Korean pharma/biotech with biologics CDMO capabilities, including biosimilars, but is significantly larger and more established.
  • SK Bioscience: Korean biopharmaceutical company with vaccine and bio CDMO capabilities. Comparable to Protium as a Korean-headquartered life-sciences services platform with development and manufacturing operations, though SK Bioscience is far larger and more diversified.
  • WuXi Biologics: Global biologics CDMO offering end-to-end development and manufacturing services for mAb, ADC, and recombinant proteins. Comparable to Protium because it competes for the same biologics outsourcing budgets across modalities, including in the Korean biosimilar market.
  • GC Biopharma (Green Cross): Korean biopharmaceutical company with plasma-derived products, vaccines, and CDMO activities. Comparable because it both produces biologics and offers CDMO-related services to Korean partners, making it a potential competitor and customer.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Protium Science social profiles

Digital presence

Protium Science financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Protium Science leadership team

Management profile

Number of profiles

Profiles2 records

Protium Science funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Protium Science M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protium Science

What does Protium Science do?

Protium Science is a CDAMO (Contract Development, Analysis, Manufacturing Organization) providing integrated biopharmaceutical development services from cell line development through GMP production. The company offers three core service pillars—CDO (contract development), CAO (contract analysis), and CMO (contract manufacturing)—with specialized capabilities in advanced modalities including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADC), peptides, and viral vectors. Services are delivered on a project-contract basis to pharmaceutical and biotech customers primarily in South Korea.

Is Protium Science a public or private company?

Protium Science is a private company. It is classified as venture growth investor backed and is currently operating.

When was Protium Science founded?

Protium Science was founded in 2021. It employs 51 to 100 people.

Where is Protium Science based?

Protium Science is headquartered in Seongnam, South Korea, in the Asia region.

How does Protium Science make money?

Three revenue lines are on record. CDAMO Services (CDO, CAO, CMO) is the primary driver. The others are ADC Development Services and investment-Linked Program.

Who are Protium Science's main competitors?

Lonza Group is listed as an others. Direct peers are ABL Bio, Celltrion, STgen Bio and Binex. Broad incumbents are Samsung Biologics, Lotte Biologics, SK Bioscience, WuXi Biologics and GC Biopharma (Green Cross).

Does Protium Science have an API?

No public API is recorded for Protium Science.

What industry is Protium Science in?

Protium Science's product category is Biopharmaceutical Contract Development and Manufacturing (CDMO/CDAMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAGAF, Analytical Development & QC Testing (Release/Stability/Potency). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals